Dubai: Imperial College London Diabetes Centre (ICLDC), part of the M42 group, has signed two agreements to advance diabetes care, highlighting its commitment to patient empowerment and personalised and precision medicine. The agreements were signed during Arab Health, which is currently taking place in Dubai.
According to Emirates News Agency, the first agreement is with healthcare technology solutions provider Medtronic. ICLDC currently cares for over 1,000 patients in Abu Dhabi who are on Medtronic’s CareLink platform. Under the new agreement, it will migrate to Medtronic’s advanced CareConnect and GALAXY platforms, which offer multiple additional features.
CareConnect provides a user-friendly digital interface, designed to be a more patient-centric alternative to the data-intensive CareLink dashboard. With customisable notifications, caregivers can stay promptly informed of critical events, such as abnormal glucose levels or device malfunctions. As an integrated remote patient monitoring system, CareConnect streamlines the patient care pathway by enhancing follow-up care and reducing the need for in-person clinical visits.
By leveraging clinical insights alongside patient data, the platform prioritises cases based on urgency, ensuring timely interventions when additional care is needed. Physicians can manage patients remotely through a tailored communications channel, while patients benefit from access to consistent care and comprehensive remote monitoring. As part of the agreement, ICLDC will also adopt Medtronic’s innovative GALAXY platform, which provides tailored reporting and insights, enabling clinicians to focus on specific patient needs and broader operational goals.
To address the challenges of managing diverse technological solutions, ICLDC is also collaborating with an innovative healthcare platform, Karaz, to streamline data integration. Currently, caregivers often need to check multiple software platforms to access data from various insulin and continuous glucose monitoring (CGM) devices. The Karaz platform will consolidate patient data into a single dashboard, simplifying caregivers’ workflow and improving efficiency.
Dr. Mai Al Jaber, CEO of Outpatient Care at M42, stated that the partnership with Medtronic reinforces their battle against diabetes by empowering patients and caregivers. Through the use of Medtronic’s advanced CareConnect and GALAXY platforms, combined with the collaboration with Karaz, ICLDC aims to establish a new benchmark for proactive, personalised patient care, giving individuals with diabetes more control and better health outcomes.
